In multiple myeloma, there has been little progress in the specific therapeutic targeting of
oncogenic mutations. Whole-genome sequencing data have recently revealed that a subset of …

As new generations of targeted therapies emerge and tumor genome sequencing discovers
increasingly comprehensive mutation repertoires, the functional relationships of mutations …

TP53 is mutated in 20–25% of aggressive B‐cell lymphoma (B‐NHL). To date, no studies
have addressed the impact of TP53 mutations in prospective clinical trial cohorts. To evaluate …

The tumour microenvironment and genetic alterations collectively influence drug efficacy in
cancer, but current evidence is limited and systematic analyses are lacking. Using chronic …

Drug combinations that target critical pathways are a mainstay of cancer care. To improve
current approaches to combination treatment of chronic lymphocytic leukemia (CLL) and gain …

While recurrent mutations in CLL have been extensively catalogued, how driver mutations
affect disease phenotypes remains incompletely understood. To address this, we performed …

The tumour microenvironment and genetic alterations collectively influence drug efficacy in
cancer, but current evidence is limited to small scale studies and systematic analyses are …

Introduction: The impact of mutations and pathway deregulation for drug sensitivity is only
partly understood. Here we systematically investigated heterogeneity of drug response and …

6519 Background: Thorough understanding of genetic lesions in cancer and targeted
intervention against driver mutations are beginning to transform cancer treatment. An activating …